This is a phase 2 randomized, double-blind controlled study to test the effect of omecamtiv mecarbil on progressive doses in patients with dyspnoea and ventricular dysfunction who were admitted for acute exacerbation of heart failure. The primary endpoint of the study was to evaluate the response in dyspnea after a 48-h infusion of omecamtiv mecarbil compared with placebo. A secondary objective was safety and tolerability of different doses of the drug. 613 patients were randomized to study drug versus placebo; no significant differences in terms of dyspnea. A trend in favor of the drug was observed in the highest dose group. There was a significant difference in systolic ejection time.
John%20R%20Teerlink%20_slides
John R Teerlink
2013-09-03
Original title: ATOMIC-AHF: Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure
